Can The U.S. Cannabis Industry Catch Up Internationally?
Cannabis export readiness review
The United States has one of the largest cannabis markets in the world, but it remains a minor participant in the international medical cannabis trade. Canada, Germany, Australia, Portugal, Thailand, Denmark, South Africa, and other countries have spent years developing import and export relationships while American operators remained largely confined to individual state markets. Federal treatment of qualifying medical cannabis changed significantly in 2026, potentially creating new international opportunities, but U.S. operators will still need to overcome pharmaceutical quality standards, logistics, pricing, permits, and competitors with a substantial head start.
Quick facts
• Canadian cannabis retailers generated a record CAD $517.8 million in sales during June 2026
• Germany imported medical cannabis from 22 countries between 2024 and 2026, according to data cited from German regulators
• Canada remains Germany's largest foreign supplier, followed by major European suppliers including Portugal and Denmark
• Germany imported roughly 205 metric tons of medical cannabis during 2025
• Australia imported 81,119 kilograms of cannabis in 2025
• Canada supplied 49,107 kilograms of Australia's 2025 imports
• Thailand supplied 20,658 kilograms after supplying only 1,093 kilograms the year before
• Official Australian data shows the United States supplied only 85 kilograms in 2025, demonstrating that current U.S. participation exists but remains extremely small
• Qualifying state licensed medical cannabis received Schedule III treatment under a federal rule effective in 2026
• Federal rules still require applicable DEA registration and import or export permits for qualifying medical cannabis
• Foreign markets can impose their own pharmaceutical manufacturing, testing, import, and quality requirements
• The universal operator lesson is simple: international market access depends on quality, cost, compliance, logistics, and relationships, not just the ability to grow cannabis
If international medical cannabis is part of your future growth strategy, complete our quick Puro Risk intake form so you can map manufacturing, product compliance, transportation, contracts, insurance, and market access exposure before committing capital to exports.
Why the United States is starting from behind
American cannabis operators built enormous cultivation and retail capacity, but most of that infrastructure was designed around state borders.
International operators developed differently.
Canadian companies gained years of experience with federal export permits, pharmaceutical buyers, overseas shipping, foreign quality standards, and international supply contracts. Portugal became a major European production hub. Thailand rapidly expanded exports to Australia. Germany built relationships with suppliers across more than 20 countries.
That experience creates an advantage that American companies cannot reproduce immediately.
Why medical rescheduling changes the opportunity
Federal policy shifted significantly in April 2026 when qualifying state licensed medical cannabis received Schedule III treatment.
The federal rule also specifically addressed import and export permit requirements for qualifying medical cannabis.
That creates a clearer regulatory pathway than operators had when state licensed cannabis remained entirely within Schedule I.
It does not create automatic permission to export.
Companies still need applicable federal registrations and permits, legal authorization in the destination country, compliant products, acceptable manufacturing systems, and transportation procedures that satisfy controlled substance requirements.
Why Germany shows how competitive the market has become
Germany has become the largest destination for international medical cannabis supply.
International Cannabis Business Conference reports that Germany imported cannabis from 22 countries between 2024 and 2026.
Canada currently leads that supply network, but Portugal, Denmark, North Macedonia, the Czech Republic, and other producers are competing for buyers.
American companies entering Germany would therefore not be joining an undeveloped market.
They would be competing against suppliers that already understand European pharmaceutical distribution, import procedures, buyer expectations, and pricing.
Why Australia offers another warning
Australia imported 81,119 kilograms of cannabis in 2025.
Canada supplied approximately 61 percent, but its volume declined while Thailand expanded from just over 1,000 kilograms in 2024 to more than 20,000 kilograms in 2025.
The United States supplied only 85 kilograms.
That number is important because it shows the U.S. is not completely absent from international trade, but its current presence is extremely small compared with established exporters.
International market share can also change quickly when a lower cost supplier meets the required quality standards.
Why cost may be the biggest challenge
The United States can produce large amounts of cannabis.
The harder question is whether American operators can produce medical cannabis that meets international requirements at a price buyers will accept.
Cultivators in countries with lower labor, energy, land, and operating costs can create significant pricing pressure.
Long distance transportation adds another expense. Medical products also require strong testing, documentation, packaging, security, quality systems, and supply consistency.
If international buyers are part of your long term plan, complete the Puro Risk intake form to identify production, quality, logistics, contract, and insurance risks before investing in additional capacity.
Conclusion
The United States can become a meaningful participant in international medical cannabis, but market size at home does not guarantee success abroad.
Canada and Europe already have established infrastructure. Thailand, South Africa, Colombia, Portugal, and other producing countries can compete aggressively on cost. Importing countries are also increasing their own domestic production.
American operators will need more than cultivation capacity.
The companies most likely to compete internationally will understand pharmaceutical quality, DEA requirements, foreign import rules, transportation, supply contracts, customer concentration, pricing, and reliable production.
The universal lesson is straightforward. Global cannabis is becoming a real international trade market, and the United States is entering after many competitors have already learned how to operate in it.
Educational note: This article is for education only and is not legal, regulatory, medical, financial, investment, pharmaceutical, international trade, DEA, product compliance, tax, or insurance advice.
What to do this week
• Identify which existing facilities could realistically satisfy international medical product standards
• Compare production costs with major international suppliers
• Review DEA registration and export permit requirements for qualifying medical cannabis activity
• Select target countries based on demand, pricing, quality rules, and import requirements
• Review transportation, security, product liability, cargo, and contract exposure
• Build an international expansion model without assuming federal rescheduling automatically creates export rights
FAQ
Is the United States currently exporting medical cannabis?
Yes, but current participation remains extremely limited. Official Australian data recorded only 85 kilograms imported from the United States during 2025.
Does Schedule III automatically allow U.S. cannabis companies to export?
No. Schedule III treatment does not eliminate DEA registration, permit, state law, destination country, product quality, and other regulatory requirements.
Which country is currently the largest medical cannabis import market?
Germany has become the leading international destination for medical cannabis imports.
Who currently dominates international cannabis exports?
Canada remains one of the dominant suppliers, while Portugal, Denmark, Thailand, South Africa, Colombia, and other countries are expanding their positions.
Why could GMP standards be challenging for U.S. operators?
International medical markets often require pharmaceutical manufacturing and quality systems that differ from the state focused production systems many American cannabis facilities were built around.
What is the biggest operator takeaway?
International expansion should be treated as a pharmaceutical supply chain strategy, not simply an opportunity to sell excess cultivation capacity overseas.
Cannabis export logistics review
You might also like
SOURCES
International Cannabis Business Conference, Can The U.S. Cannabis Industry Catch Up Internationally?, August 30, 2026
https://internationalcbc.com/can-the-u-s-cannabis-industry-catch-up-internationally/
The report highlights Canada's record June retail sales, Germany's international supplier network, Australia's import growth, and the competitive challenges facing future U.S. exporters.
Australian Government Office of Drug Control, Australian Cannabis Data: Import, Export, Production And Stock, updated August 19, 2026
https://www.odc.gov.au/australian-cannabis-data-import-export-production-and-stock
Official Australian data reports 81,119 kilograms of imports in 2025, including 49,107 kilograms from Canada, 20,658 kilograms from Thailand, and 85 kilograms from the United States.
U.S. Department of Justice, Schedule III Treatment For Qualifying Medical Cannabis And Corresponding Import And Export Permit Requirements, April 2026
https://www.justice.gov/opa/media/1437751/dl
The federal rule places qualifying state licensed medical cannabis into Schedule III and specifically subjects covered cannabis to DEA import and export permit requirements.
Researchers found that biogenic silver nanoparticles can trigger cannabis cell cultures to produce measurable THC and CBD even when untreated cells produce none. The early research could eventually influence cannabinoid manufacturing, pharmaceutical supply, quality control, intellectual property, and the economics of traditional cultivation.